The University of Georgia College of Pharmacy Department of Pharmaceutical & Biomedical Sciences invites you to attend |
The 2023 Chu Lectureship The Male Pill: Are We There Yet? |
Gunda I. Georg, PhD Regents Professor, Department of Medicinal Chemistry Robert Vince Endowed Chair
McKnight Presidential Chair Director, Institute for Therapeutics Discovery and Development (ITDD) Faculty, MS and PhD Programs in Molecular Pharmacology and Therapeutics (MPaT) University of Minnesota College of Pharmacy |
Wednesday, March 15, 2023 | 9:00 a.m.
UGA College of Pharmacy The David and Jane Chu Auditorium 101 Pharmacy South Reception immediately following the lecture. A Zoom link will be available for those unable to attend in person. |
Questions? Contact Toni Phelabaum at
amp@uga.edu or 706-542-1914. |
Lecture Abstract:
"To provide couples with additional safe and reversible options for contraception, the development of non-hormonal contraceptives for both men and women is highly desirable to assist with family planning and reducing unintended pregnancies. In collaboration with the Wolgemuth group at Columbia University we have discovered the non-hormonal male contraceptive agent YCT529 that is targeting retinoic acid receptor alpha, a validated male contraceptive target. Together with our industrial partner Your Choice Therapeutics (YCT) we are developing YCT529 for first-in-human clinical trials. The presentation will discuss the discovery and development of YCT529 including the preclinical efficacy in mouse and non-human primates."
About the Chu Lectureship:
The Chu Lectureship was established to bring nationally and internationally recognized leaders in drug discovery to UGA, and to honor the outstanding accomplishments and contributions of Distinguished Research Professor, David Chu.
Dr. Chu joined UGA in 1982, and has spent his entire career researching new drugs for the treatment of viral infections and cancer. In 1986, Dr. Chu established the Drug Discovery Group in the UGA College of Pharmacy. The group's research focus is on the design and discovery of compounds for treatment of various emerging infectious diseases. Chu and his collaborators have discovered five chemotherapeutic agents against cancer, AIDS, shingles, and Hepatitis B virus. Some of these compounds are currently undergoing clinical and preclinical trials, and an antiviral agent (Clevudine) is available for the treatment of chronic Hepatitis B infection in Asian countries.
|
